Lobachevsky Pavel N, Martin Roger F
Research Laboratories, Peter MacCallum Cancer Centre, St Andrew's Place, East Melbourne, Victoria 3002, Australia.
Int J Radiat Biol. 2004 Nov-Dec;80(11-12):915-20. doi: 10.1080/09553000400017754.
The Auger emitting isotope 123I has a much shorter half-life (13.2 hours), than 125I, the prototype Auger emitter. Monte Carlo simulations and cell culture studies indicate that decay of 123I covalently incorporated into DNA is about half as effective as 125I in terms of DNA breakage and cytotoxicity. The aim of the present study is to assess the DNA breakage efficacy of 123I that is non-covalently associated with DNA, using the minor groove binding ligand iodoHoechst 33258.
Plasmid (pBR322) DNA was incubated with mixtures of [123I]- and [125I]-iodoHoechst 33258, and DNA double strand breakage (DSB) assessed by assaying the relative amounts of intact, relaxed and linear plasmid forms separated by agarose gel electrophoresis. This "double-label" approach provides a measure of the ratio of probabilities of DSB formation per decay for these two isotopes, with much higher precision than comparing the absolute probabilities for the individual isotopes, principally because it avoids the requirement to accurately determine the fraction of bound ligand.
Our results indicate that the ratio of DSB probability per decay of 123I to that of 125I is 0.63 +/- 0.03. The ratio does not change much with addition of dimethyl sulfoxide (DMSO) to the incubation mixture--0.65 +/- 0.03. This ratio agrees well with the relative efficiency of the two isotopes reported in theoretical and experimental studies, using various endpoints.
In considering the possible exploitation of the Auger effect in cancer therapy, the modest decrease in DNA breakage efficacy for 123I compared to 125I might be more than compensated for by the advantage of the much shorter half-life. The 60-day half-life of 125I imposes severe limitations in terms of radiation protection.
与原型俄歇电子发射体125I相比,发射俄歇电子的同位素123I的半衰期(13.2小时)要短得多。蒙特卡罗模拟和细胞培养研究表明,共价结合到DNA中的123I衰变在DNA断裂和细胞毒性方面的有效性约为125I的一半。本研究的目的是使用小沟结合配体碘代赫斯特33258评估与DNA非共价结合的123I的DNA断裂效力。
将质粒(pBR322)DNA与[123I]-和[125I]-碘代赫斯特33258的混合物一起孵育,并通过测定琼脂糖凝胶电泳分离的完整、松弛和线性质粒形式的相对量来评估DNA双链断裂(DSB)。这种“双标记”方法提供了这两种同位素每次衰变形成DSB的概率比的度量,比比较单个同位素的绝对概率具有更高的精度,主要是因为它避免了准确确定结合配体分数的要求。
我们的结果表明,123I每次衰变的DSB概率与125I的DSB概率之比为0.63±0.03。向孵育混合物中添加二甲基亚砜(DMSO)后,该比值变化不大——为0.65±0.03。该比值与使用各种终点的理论和实验研究中报道的两种同位素的相对效率非常吻合。
在考虑俄歇效应在癌症治疗中的可能应用时,与125I相比,123I的DNA断裂效力适度降低可能会被其短得多的半衰期所带来的优势所弥补。125I的60天半衰期在辐射防护方面带来了严重限制。